Lakhasly

Scientific Name: Indomethacin

Trade Names: Indocin Indocid

Classification: Nonsteroidal Anti-Inflammatory Drug (NSAID)

Prostaglandin Synthesis Inhibitor

Mechanism of Action: Indomethacin works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins.Always consult a healthcare provider for specific treatment recommendations### Alternatives:

• Ibuprofen lysine: Another NSAID used for PDA closure, with a similar mechanism of action but potentially fewer renal side effects.### Monitoring:
• Renal function: Monitor urine output, serum creatinine, and blood urea nitrogen (BUN).It is typically used in neonates, especially preterm infants, where the ductus arteriosus fails to close spontaneously.Contraindications: Active bleeding or significant risk of bleeding intracranial hemorrhage, gastrointestinal bleeding

Thrombocytopenia** (low platelet count).Indications: Closure of hemodynamically significant PDA in premature infants.### Dosage and Administration:

• Dosage: Typically, indomethacin is administered intravenously in three doses over 24-48 hours.- Surgical ligation: If pharmacological treatment fails or is contraindicated, surgical closure of the PDA may be necessary.By inhibiting their production, indomethacin promotes the closure of the ductus arteriosus.### Side Effects:
• Renal: Reduced urine output, renal dysfunction, or acute kidney injury.- Metabolism: Primarily hepatic.

Scientific Name:
Indomethacin

Trade Names:
Indocin
Indocid

Classification:
Nonsteroidal Anti-Inflammatory Drug (NSAID)

Prostaglandin Synthesis Inhibitor

Mechanism of Action:
Indomethacin works by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins.
Prostaglandins are responsible for keeping the ductus arteriosus open. By inhibiting their production, indomethacin promotes the closure of the ductus arteriosus.

Indications:
Closure of hemodynamically significant PDA in premature infants.
It is typically used in neonates, especially preterm infants, where the ductus arteriosus fails to close spontaneously.

Contraindications:
Active bleeding or significant risk of bleeding
intracranial hemorrhage, gastrointestinal bleeding

Thrombocytopenia** (low platelet count).

• 
  Necrotizing enterocolitis (NEC) or other gastrointestinal conditions.


• 
  Renal impairment or significant renal dysfunction.


• 
  Hypersensitivity to indomethacin or other NSAIDs.
  


• 
  Congenital heart disease where the PDA is necessary for survival (e.g., certain types of cyanotic heart disease).

Dosage and Administration:

• 
  Dosage: Typically, indomethacin is administered intravenously in three doses over 24-48 hours. The exact dosage depends on the infant's weight and postnatal age.


• 
  Route: Intravenous (IV) is the preferred route for neonates.


• 
  Frequency: Usually given every 12-24 hours, depending on the protocol.

Side Effects:

• 
  Renal: Reduced urine output, renal dysfunction, or acute kidney injury.


• 
  Gastrointestinal: Increased risk of necrotizing enterocolitis (NEC), gastrointestinal bleeding.


• 
  Hematologic: Thrombocytopenia, bleeding disorders.


• 
  Cardiovascular: Hypertension, fluid retention.


• 
  Other: Hyperbilirubinemia, hypoglycemia, or electrolyte imbalances.

Monitoring:

• 
  Renal function: Monitor urine output, serum creatinine, and blood urea nitrogen (BUN).


• 
  Platelet count: Regular monitoring to detect thrombocytopenia.


• 
  Gastrointestinal symptoms: Watch for signs of NEC, such as abdominal distension, feeding intolerance, or bloody stools.


• 
  Cardiac function: Echocardiography to assess PDA closure.

Alternatives:

• 
  Ibuprofen lysine: Another NSAID used for PDA closure, with a similar mechanism of action but potentially fewer renal side effects.


• 
  Surgical ligation: If pharmacological treatment fails or is contraindicated, surgical closure of the PDA may be necessary.

Precautions:

• Use with caution in infants with impaired renal or hepatic function.


• Avoid concurrent use with other nephrotoxic drugs.


• Monitor for signs of infection, as NSAIDs can mask fever and other signs of inflammation.

Pharmacokinetics:

• 
  Half-life: Approximately 12-20 hours in neonates.


• 
  Metabolism: Primarily hepatic.


• 
  Excretion: Renal excretion of metabolites.

Clinical Considerations:

• Indomethacin is most effective when used within the first 2 weeks of life in preterm infants.


• The success rate of PDA closure with indomethacin is approximately 70-80%, depending on the infant's age and weight at the time of treatment.

This information is intended for educational purposes and should not replace professional medical advice. Always consult a healthcare provider for specific treatment recommendations